Ocugen, Inc. (OCGN)
NASDAQ: OCGN · IEX Real-Time Price · USD
1.345
-0.045 (-3.24%)
May 2, 2024, 9:59 AM EDT - Market open
Ocugen Revenue
In the year 2023, Ocugen had annual revenue of $6.04M with 142.60% growth. Revenue in the quarter ending December 31, 2023 was $6.04M with 142.60% year-over-year growth.
Revenue (ttm)
$6.04M
Revenue Growth
+142.60%
P/S Ratio
59.26
Revenue / Employee
$92,862
Employees
65
Market Cap
346.11M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
Dec 31, 2022 | 2.49M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 43.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 26.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Health Catalyst | 295.94M |
Harrow Health | 130.19M |
Heron Therapeutics | 127.04M |
Esperion Therapeutics | 116.33M |
CytomX Therapeutics | 101.21M |
Precigen | 6.23M |
OCGN News
- 2 hours ago - Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress - GlobeNewsWire
- 20 hours ago - DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm - Accesswire
- 23 hours ago - IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm - PRNewsWire
- 2 days ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors - Business Wire
- 3 days ago - Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 - GlobeNewsWire
- 4 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN - PRNewsWire
- 5 days ago - ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN - PRNewsWire
- 6 days ago - UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - GlobeNewsWire